Recombinant urate oxidase (rasburicase) lowers uric acid levels rapidly to very low levels at the labeled dose of 0.15-0.2 mg/kg daily for 5 days. Our past experience showed that a lower dose (3 mg) lowered uric acid levels sufficiently in most patients. A retrospective review was conducted to determine the effect of a fixed 3 mg dose of rasburicase in 43 adult patients with cancer undergoing hematopoietic stem cell transplantation or receiving chemotherapy who had elevated or rising uric acid levels (6.4-16.8 mg/dl; median 9.6). Six patients received a second dose of rasburicase (3 mg in four patients and 1.5 mg in two patients) 24 h later. Patients received allopurinol, adequate hydration, as well as other supportive therapy as required. Uric acid levels declined by 6-95% (median 43%) within the first 24 h after rasburicase administration, and levels at 48 h were 9-91% (median 65%) lower than the baseline levels. Serum creatinine changed by p10% in 21 patients, increased by 410% in four patients and decreased by 410% in 18 patients. No significant renal dysfunction developed in any of the patients. We conclude that rasburicase is effective in lowering uric acid levels at a fixed dose of 3 mg, which is much lower than the recommended dose.
Introduction
Hyperuricemia is one of the metabolic abnormalities seen in patients with tumor lysis syndrome (TLS). 1 The standard management of hyperuricemia consists of hydration, alkalinization of the urine and the administration of allopurinol. Allopurinol, available in oral as well as intravenous formulations, affects purine metabolism by inhibiting xanthine oxidase, an enzyme responsible for the conversion of hypoxanthine to xanthine, and xanthine to uric acid. 2 It lowers serum and urine uric acid levels by inhibiting uric acid formation, but has no direct effect on existing uric acid in the blood.
Urate oxidase is a peroxisomal enzyme catalyzing the oxidation of uric acid to allantoin. This enzyme is present in most mammals, except humans and certain other primates. 3 Murine urate oxidase has been used successfully to treat hyperuricemia. 4 It reduces uric acid levels rapidly by converting uric acid to allantoin. Allantoin is five-to 10-fold more soluble than uric acid and is readily excreted. Expression of the gene encoding urate oxidase in yeast yields recombinant enzyme in therapeutically useful quantities. 5 Recombinant urate oxidase (rasburicase) has been found to be useful prophylactically and therapeutically for hyperuricemia in children 6 and adults. 7 Rasburicase administration at the recommended dose of 0.2 mg/kg for 3-7 days results in dramatically reduced levels of serum uric acid, usually substantially lower than the lower limit of normal. 6, 7 Only one of 12 patients receiving 0.15 mg/ kg rasburicase (25% dose reduction) developed transient hyperuricemia, 7 suggesting that the recommended dose may be higher than necessary. Limited experience suggests that lower doses of rasburicase are also effective in lowering uric acid levels. 8, 9 After seeing an excellent, sustained response with a single dose of rasburicase dose at 0.2 mg/kg ideal body weight (total dose 12 mg) in a significantly obese patient, we decided to use lower doses of the drug in adult patients. Our early experience with variable low doses (1.5-12 mg) suggested that 3 mg appeared to be effective in most patients, 10 and this dose was adopted in clinical practice. We present a retrospective analysis of our experience with a fixed 3 mg dose of rasburicase in 43 cancer patients with elevated or increasing uric acid levels. Oral allopurinol was administered as required to inhibit uric acid formation. Patients were hydrated, and received chemotherapy as well as other supportive therapy (including urine alkalinization and hemodialysis) as required based upon frequent clinical and biochemical monitoring, and the assessment of the treating physician. Table 1 shows patient characteristics. All patients had hematologic malignancies and were on chemotherapy (including high-dose chemotherapy) or were about to start receiving it, hyperuricemia being secondary to tumor burden and therapy. Two of the three patients undergoing hemodialysis had myeloma with end-stage renal disease, and were on hemodialysis before receiving high-dose melphalan for autotransplantation. The third patient had relapsed following an allograft for acute myeloid leukemia, and was on hemodialysis after developing renal failure on salvage chemotherapy.
Patients and methods

Records of all (n
At baseline, 15 patients had additional laboratory manifestations (two or more of the following: elevated lactate dehydrogenase (LDH), elevated phosphorus, elevated potassium and low calcium) suggestive of TLS. Five of the 10 non-Hodgkin's lymphoma (NHL) patients had high-grade disease and the rest had follicular or small lymphocytic lymphoma.
Results
Thirty-seven patients received a single 3 mg dose of rasburicase. Six patients received an additional dose of 1.5 mg (n ¼ 2) or 3 mg (n ¼ 4) 24 h after the first dose based on biochemical assessment (persistent hyperuricemia).
Serum uric acid levels declined by 6-95% (median 43%) within the first 24 h after rasburicase administration, and levels at 48 h were 9-91% (median 65%) lower than the baseline levels. Every single uric acid level at 48 h was within the normal range (under 8 mg/dl). Figures 1 and 2 show the actual and percent changes in serum uric acid at 24 and 48 h compared to baseline.
The uric acid levels at baseline, 24 and 48 h in the six patients who received an additional dose of rasburicase at 24 h were 11.6/8.4/6.5, 16.4/8.4/6.2, 8.6/7.0/2.5, 9.5/8.9/3.2, 9.6/3.6/2.0 and 11.4/7.9/5.9, respectively. Although the baseline uric acid levels were comparable between these six patients and the rest (median 10.5 vs 9.5; P ¼ 0.31), the 24-h levels were higher (median 8.2 vs 5.3; P ¼ 0.034), and the percent reduction at 24 h lower (median 29 vs 43%; P ¼ 0.11). However, the 48-h levels (median 4.5 vs 3.8; P ¼ 0.44) and percent reduction at 48 h (median 64 vs 65%; P ¼ 0.88) were comparable. 
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The uric acid reduction in patients weighing p80 kg (n ¼ 18; median 42%) was comparable (P ¼ 0.21) to that seen in heavier patients (n ¼ 25; median 43%). Similarly, the reduction in patients with a baseline uric acid level of o10 mg/dl (n ¼ 25; median 43%) was comparable (P ¼ 0.92) to that with X10 mg/dl (n ¼ 18; median 46%). The weights of the six patients requiring a second dose of rasburicase (70, 77, 77, 99, 99 and 103 kg) were not significantly different from those who did not need a second dose (50-146 kg; median 86; P ¼ 0.94).
At 24 h, serum creatinine changed by p10% in 21 patients, increased by 410% in four patients and decreased by 410% in 18 patients. In the four patients experiencing increased creatinine, the baseline and 24-h values were 1.7/ 2.3, 1.9/2.3, 2.8/3.3 and 1.5/1.7, respectively. However, the 48-h and 7-day values in these patients were 1.8/1.4, 2.3/1.7, 3.4/3.0 and 1.6/1.1, respectively, suggesting stabilization or improvement in renal dysfunction. Figure 3 shows the change in serum creatinine over 48 h. No clinically significant renal dysfunction developed in any of the patients over a period of a week after rasburicase administration, with no patient (excluding the three already on hemodialysis) requiring dialysis. There was no difference in outcome between patients who had undergone HSCT and those who had not.
The extent of decline in uric acid at 24 h was comparable for the 15 patients with laboratory features of TLS and the rest (P ¼ 0.88). Similarly, the extent of change in the serum creatinine levels at 24 h (P ¼ 0.72) and 48 h (P ¼ 0.61) was also comparable between those with and without features of TLS.
The actual dose administered, 3 mg (n ¼ 37), 4.5 mg (n ¼ 2) and 6 mg (n ¼ 4), was a fraction of what the recommended dose would have been at 37.5-109.5 mg (based on 0.15 mg/kg daily for 5 days) or 50-146 mg (based on 0.2 mg/kg daily for 5 days). Based on the Red Book price of rasburicase, $387 for a 1.5 mg vial, the cost of the total amount of rasburicase used (144 mg) for these 43 patients was $37 152. The cost of the total amount of rasburicase used at the dose of 0.15 mg/kg daily for 5 days (2842 mg) would have been $733 172. The cost of the total amount of rasburicase used at the dose of 0.2 mg/kg daily for 5 days (3789 mg) would have been $977 562.
Discussion
Our data show that in most clinical situations, a low dose of rasburicase is sufficient to lower uric acid levels and appears as effective as the significantly higher dose explored in previous studies. 6, 7, 11 It should be noted that in the United States, rasburicase is approved for therapy only in children. Therefore, there is no recommended dose for adults who may require it under appropriate clinical circumstances.
Rasburicase is an extremely expensive drug. Based on its Red Book price ($387 for a 1.5 mg vial) and published dose of 0.2 mg/kg, 7 a day's dose of the drug for a 70 kg adult costs $3870. The economic burden of using this widely, including in diseases where TLS is an insignificant concern, for several days as advocated by some 7 is enormous. However, because of the efficacy of the drug in preventing TLS and its sequelae, its use has apparently been found to be cost-effective at the recommended doses. 11 In contrast, oral allopurinol costs 14 cents per day for 300 mg. Of course, it should be noted that the use of the two is not mutually exclusive. Allopurinol inhibits uric acid formation, whereas rasburicase enhances uric acid excretion. Indeed, under most circumstances, it would make sense to use both drugs together.
Wossmann et al. 12 analyzed the incidence and complications of TLS in children with acute lymphoblastic leukemia (ALL) or Burkitt's lymphoma and elevated LDH who did not or did receive urate oxidase prophylactically with chemotherapy. Among children with lymphoma who did not receive urate oxidase prophylactically, the incidence of TLS and anuria was 16 and 9%, not significantly different from 12 and 6% for those who did. The incidence of sepsis was comparable (5%). In children with ALL, the incidence of anuria was significantly higher (15%) without urate oxidase than with (4%; P ¼ 0.03). However, it was unclear if this conferred a survival benefit. Similarly, a randomized study of rasburicase and allopurinol in children showed faster decline in uric acid with rasburicase therapy without any obvious short-term survival advantage for rasburicasetreated patients. 6 A European multi-center study of rasburicase in 100 patients with aggressive NHL -only 11% of whom were hyperuricemic -found normalization of serum uric acid levels within 4 h of the first dose. 7 The dose of rasburicase used in the study was 0.2 mg/kg daily for 3-7 days (median 3). This single-arm study concluded that rasburicase was 'the treatment of choice' to control uric acid and prevent TLS in adult patients with aggressive NHL. This study was not designed to address questions of improved outcome, but focused solely on biochemical parameters. Additionally, allopurinol use was not permitted in this study for the first week. As the mechanisms of action of rasburicase and allopurinol are different, it would appear to be more logical biochemically to reduce grossly elevated uric acid levels with one dose of rasburicase with concomitant allopurinol use to reduce uric acid formation. 
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Based on published data with the full dose of the drug, it is clear that the rate of fall of uric acid levels was slower with the 3 mg dose. What is not clear is if a rapid decline in uric acid to very low levels offers any practical benefit. The limited available data do not suggest any such benefit. 6, 7, 12 While our data are insufficient to support such a recommendation, it may be desirable to use a higher dose (6 mg) in those with uric acid levels that are over twice the upper limit of normal. The half-life of rasburicase is 21 h, and thus daily administration would not be expected to be necessary. This is borne out by our observations, which make it clear that continued daily administration of the drug is unnecessary in most patients because uric acid levels remain low for a prolonged period after a single dose. Monitoring uric acid levels regularly and repeating drug administration only if necessary is adequate.
In the context of the activity of the drug, 6, 7, 12 strong advocacy for its widespread use 7 and its cost, we believe our observations, despite their limitations, are of value in designing new studies and managing patients. The limitations of these data are their retrospective and nonsystematic nature. It should be emphasized that this was not a systematic dose-reduction study, but clinical practice adopted based on a serendipitous observation in a single patient. The strength of our analysis is that the observations have been made under actual clinical circumstances (not according to a tightly defined monitoring and treatment protocol but based on laboratory parameters and clinical circumstances), and therefore are likely to be easily applicable to daily practice.
Indeed, it could be argued that some of the patients treated by us had only modestly elevated uric acid levels with normal renal function, and need not have received rasburicase at all. This only serves to underscore the fact that the drug need not be overused or overdosed.
The decline in uric acid and creatinine was similar for patients who had evidence of TLS and those who did not (i.e. those with isolated hyperuricemia). This is not surprising because one would not expect any other abnormality of TLS apart from hyperuricemia and renal dysfunction secondary to hyperuricemia to be impacted by rasburicase. It also suggests that the lower dose is appropriate even in patients with TLS.
The importance of using the drug judiciously is in limiting the high expenditure associated with a potentially useful supportive care measure -but one that has not been shown to influence survival beneficially -in an era of skyrocketing health-care costs. Cost of newer medications is a matter of grave concern even with drugs that affect survival beneficially. 13 The French study advocated the use of rasburicase in all patients with lymphoid diseases including chronic lymphocytic leukemia. This recommendation is not based upon any data, and if followed, could cost more than $500 million a year in the US.
Hematopoietic stem cell transplantation is an expensive procedure, and controlling drug cost during or after HSCT is desirable. If rasburicase use is required to treat hyperuricemia post transplant, our data support the use of the drug at a low dose to achieve desired results at an acceptable cost.
Although formal dose-finding studies of lower doses may be desirable, we suggest 3 mg as the initial dose for most adults followed by additional 3 mg doses as required based upon close monitoring of uric acid levels. Unlike clinical trials where allopurinol was not used, 7 oral (or intravenous for those unable to take the drug orally) allopurinol must be used in conjunction with rasburicase and other supportive measures as is essential in prophylaxis or therapy of hyperuricemia or TLS.
Whether rasburicase should be used routinely or not, and whether it offers benefits that are more tangible than a rapid decline in uric acid levels -such as significantly reduced renal failure, elimination of the requirement for dialysis or improved survival -remains to be determined. However, the successful use of lower doses of rasburicase, as demonstrated here and elsewhere, 8, 9 represents an attractive alternative at an expense that could be justifiable in patients at risk of complications of hyperuricemia.
We conclude that in appropriate clinical circumstances, using a low dose of rasburicase and repeating the dose as required based on frequent serum uric acid monitoring is safe and effective in correcting hyperuricemia. We recommend using a single 3 mg dose of rasburicase initially followed by regular monitoring of uric acid levels. Another dose of 3 mg should be administered if the tempo of uric acid decline is slow or the magnitude of the decline is insufficient.
